A histological response to antiviral therapy for chronic hepatitis C in patients who failed to achieve a sustained virological response

Cite item

Full Text


The paper presents the results of combination antiviral therapy (AVT) in 2 patients with chronic hepatitis C (CHC) unresponsive to AVT. Both patients are classified as difficult to treat (genotype 1b, a high viral load, overweight). 1.5 years after the termination of a course of AVT, histological examination of biopsy specimens revealed a histological response in one patient and significant histological worsening in the other. The specific features of the development of a histological response to AVT and possible reasons for its lack are discussed by the example of the described patients.

Full Text

Гистологический ответ на противовирусную терапию хронического гепатита С у пациентов, не достигших устойчивого вирусологического ответа. - Аннотация. Представлено клиническое наблюдение результатов комбинированной противовирусной терапии (ПВТ) у 2 больных хроническим гепатитом С (ХГС), не ответивших на ПВТ. Оба больных относятся к категории "трудных" для лечения (генотип 1b, высокая вирусная нагрузка, избыточная масса тела). Через 1,5 года после окончания курса ПВТ при гистологическом исследовании биоптатов выявлены гистологический ответ у одного больного и значительное гистологическое ухудшение у другого. На примере описанных больных обсуждаются особенности развития гистологического ответа на ПВТ и возможные причины его отсутствия.

About the authors

A M Riumin

O V Korochkina

Email: selelarion@mail.ru


  1. Reichard O., Glaumann H., Fryden A. et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-922.
  2. Saracco G., Rosina F., Abate M.L. et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa 2b. Hepatology 1993; 18: 1300-1305.
  3. Tsubota A., Kumada H., Chayama K. et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection. J Hepatol 2007; 27: 49-55.
  4. George S. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738.
  5. Pol S., Carnot F., Nalpas B. et al. Reversibility of hepatitis C virus-related cirrhosis. Human Pathol 2004; 35 (1):107-112.
  6. Toccaceli F., Laghi V., Capurso L. et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126-133.
  7. Kumar D., Farrell G., Fung C. et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272.
  8. Camma C., Di Bona D., Schepis F. et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004; 39: 333-342.
  9. Guerret S., Desmoulière A., Chossegros P. et al. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 1999; 6 (2): 125-133.
  10. Poynard T., McHutchison J., Davis G. et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies